Strontium chloride [89Sr] (Strontii [89 Sr] chloridum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic agents

Radioprophylactic and radiotherapeutic agents

Included in the formulation
  • Strontium chloride, 89Sr
    solution in / in 
    Federal Center for Design and Development of Nuclear Medicine Facilities of FMBA of Russia, FSUE     Russia
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    V.10.B.X   Various other preparations for palliative treatment of bone metastases

    Pharmacodynamics: Has a local effect on primary and metastatic tumors of bone tissue, reduces pain in the bones. The analgesic effect occurs after the first week of treatment and reaches a maximum at week 5, lasts for 4-12 months.

    Pharmacokinetics:

    After intravenous administration, it is included in biochemical reactions similar to calcium ions. Selectively concentrated in areas of increased mineral metabolism in connection with enhanced osteogenesis. The highest concentration of the drug is observed in primary tumors and metastatic foci, in which it is retained for 100 days.

    Indications:

    It is used for the purpose of palliative treatment of bone pain in patients with bone metastases in various forms of cancer.

    ICD-10

    II.C15-C26.C26   Malignant neoplasm of other and inaccurately indicated digestive organs

    II.C30-C39.C34   Malignant neoplasm of bronchi and lungs

    II.C43-C44.C44   Other malignant neoplasms of the skin

    II.C73-C75.C73   Malignant neoplasm of thyroid gland

    II.C64-C68.C64   Malignant neoplasm of kidney, except for renal pelvis

    II.C60-C63.C61   Malignant neoplasm of prostate

    II.C51-C58.C54   Malignant neoplasm of uterine body

    II.C50.C50   Malignant neoplasm of breast

    XVIII.R50-R69.R52.1   Constant unrestrained pain

    XXI.Z40-Z54.Z51.0   Radiotherapy course (supportive)

    Contraindications:

    Compression of the spinal cord, oppression of bone marrow circulation, individual intolerance.

    Carefully:

    Urinary incontinence, obstruction of the urinary tract, diffuse hyperfixation in the bones.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intravenously slowly for 2 minutes to 150 MBq in the calculation of 2 MBq / kg. Multiplicity of injections - 12 weeks.

    The highest daily dose: 2 MBq / kg.

    The highest single dose: 150 MBq.

    Side effects:

    Feeling of heat when the drug is injected.

    The hemopoietic system: transient leukocytopenia and thrombocytopenia.

    Allergic reactions.

    Overdose:

    Cases of overdose are not noted.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    Monitoring the composition of peripheral blood.

    Instructions
    Up